These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38866910)

  • 1. The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.
    Kim SH; Lee BR; Kim SM; Kim S; Kim MS; Kim J; Lee I; Kim HS; Nam GH; Kim IS; Song K; Choi Y; Lee DS; Park WY
    Exp Mol Med; 2024 Jun; 56(6):1461-1471. PubMed ID: 38866910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
    Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
    Lowery FJ; Krishna S; Yossef R; Parikh NB; Chatani PD; Zacharakis N; Parkhurst MR; Levin N; Sindiri S; Sachs A; Hitscherich KJ; Yu Z; Vale NR; Lu YC; Zheng Z; Jia L; Gartner JJ; Hill VK; Copeland AR; Nah SK; Masi RV; Gasmi B; Kivitz S; Paria BC; Florentin M; Kim SP; Hanada KI; Li YF; Ngo LT; Ray S; Shindorf ML; Levi ST; Shepherd R; Toy C; Parikh AY; Prickett TD; Kelly MC; Beyer R; Goff SL; Yang JC; Robbins PF; Rosenberg SA
    Science; 2022 Feb; 375(6583):877-884. PubMed ID: 35113651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
    Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
    Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
    Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell surface marker-based capture of neoantigen-reactive CD8
    Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
    Peri A; Greenstein E; Alon M; Pai JA; Dingjan T; Reich-Zeliger S; Barnea E; Barbolin C; Levy R; Arnedo-Pac C; Kalaora S; Dassa B; Feldmesser E; Shang P; Greenberg P; Levin Y; Benedek G; Levesque MP; Adams DJ; Lotem M; Wilmott JS; Scolyer RA; Jönsson GB; Admon A; Rosenberg SA; Cohen CJ; Niv MY; Lopez-Bigas N; Satpathy AT; Friedman N; Samuels Y
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
    Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
    Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of neoantigen-reactive T cells from healthy donors.
    Ali M; Foldvari Z; Giannakopoulou E; Böschen ML; Strønen E; Yang W; Toebes M; Schubert B; Kohlbacher O; Schumacher TN; Olweus J
    Nat Protoc; 2019 Jun; 14(6):1926-1943. PubMed ID: 31101906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy.
    Shah RK; Cygan E; Kozlik T; Colina A; Zamora AE
    Front Immunol; 2023; 14():1301100. PubMed ID: 38149253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.